Madhu Kumar
Stock Analyst at Goldman Sachs
(2.88)
# 1,563
Out of 4,829 analysts
153
Total ratings
54.46%
Success rate
18.78%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $103.61 | +63.11% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $5.71 | +5.17% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $19.33 | +34.51% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $12.37 | +37.43% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.20 | +234.73% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $139.43 | +11.17% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $32.14 | +64.90% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $3.61 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $13.95 | +423.49% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $17.50 | +705.94% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $11.01 | +208.81% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $1.93 | +210.88% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $11.55 | +21.21% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $9.86 | +112.98% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $14.74 | -66.08% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $1.54 | +419.48% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $6.51 | +1,267.13% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.30 | +1,900.00% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.46 | +2,059.36% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $8.55 | +894.15% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.57 | +2,392.01% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $13.15 | +333.46% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.36 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.62 | +55,455.56% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $5.30 | +277.71% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.39 | +7,094.24% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $32.39 | +8.06% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.38 | +15,895.73% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $5.84 | +584.93% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $12.40 | +3,964.52% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $270.19 | -14.87% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $7.89 | +660.94% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.66 | +2,309.64% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $35.02 | -38.60% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $37.55 | -37.42% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $103.61
Upside: +63.11%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $5.71
Upside: +5.17%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $19.33
Upside: +34.51%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $12.37
Upside: +37.43%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.20
Upside: +234.73%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $139.43
Upside: +11.17%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $32.14
Upside: +64.90%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.61
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $13.95
Upside: +423.49%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $17.50
Upside: +705.94%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $11.01
Upside: +208.81%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $1.93
Upside: +210.88%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $11.55
Upside: +21.21%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $9.86
Upside: +112.98%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $14.74
Upside: -66.08%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $1.54
Upside: +419.48%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $6.51
Upside: +1,267.13%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.30
Upside: +1,900.00%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.46
Upside: +2,059.36%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $8.55
Upside: +894.15%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.57
Upside: +2,392.01%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $13.15
Upside: +333.46%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.36
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.62
Upside: +55,455.56%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $5.30
Upside: +277.71%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.39
Upside: +7,094.24%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $32.39
Upside: +8.06%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.38
Upside: +15,895.73%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $5.84
Upside: +584.93%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $12.40
Upside: +3,964.52%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $270.19
Upside: -14.87%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $7.89
Upside: +660.94%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.66
Upside: +2,309.64%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $35.02
Upside: -38.60%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $37.55
Upside: -37.42%